TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03193710

Intervention type: DRUG
Intervention: Propofol
Description: Propofol will be used for anesthesia maintenance in the total intravenous anesthesia group.

Intervention type: DRUG
Intervention: Sevoflurane
Description: Sevoflurane will be used for anesthesia maintenance in the inhalation anesthesia group.

Intervention type: DRUG
Intervention: Remifentanil
Description: Remifentanil will be used for analgesia in both groups.

Intervention type: DRUG
Intervention: Remifentanil
Description: Remifentanil will be used for analgesia in both groups.
Study: NCT00924911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322
Description: GSK1322322 1000mg
Study: NCT01371097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Resistance strength training
Description: Resistance strength training is given as circle training. The resistance is increased with regularly intervals.
Study: NCT02691845

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HE (health education)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBEX (cognitive-behavioral sessions focused on increasing and maintaining exercise)
Study: NCT04160793

Intervention type: DEVICE
Group type: OTHER
Intervention: Genital Nerve Stimulation
Description: Implantation the vaginal way a stimulation's electrode to the dorsal nerve of the clintoris in local anesthesia
Study: NCT03302728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide 15mg
Description: At commencement of study : Lenalidomide will commence at 15 mg daily for days 1-14 of each cycle. Maximum number of cycles = 16. This is a dose finding study so doses will be adjusted depending on toxicity assessment over the course of the study. Dose may vary from 5 mg -25 mg daily depending on dose escalation results and recommendation of safety committee

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin 1.8 mg/Kg
Description: At commencement of study : Brentuximab vedotin 1.8mg/kg IV on day 1, repeated every 21 days. Maximum number of cycles = 16. This is a dose finding study so doses will be adjusted depending on toxicity assessment over the course of the study. Dose may be either 1.2 mg/Kg q21 days or 1.8 mg/kg q21 days depending on dose escalation results and recommendation of safety committee
Study: NCT00819416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% albumin
Description: 5% albumin for the first 7 days of care in the ICU

Intervention type: DRUG
Group type: OTHER
Intervention: Normal Saline
Description: Normal Saline for the first 7 days of care in the ICU
Study: NCT02898376

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocopherol acetate
Description: 500 mg bid during at least 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocopherol acetate
Description: 500 mg bid during at least 6 months
Study: NCT01699815

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Study: NCT00324519

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley bulb

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Study: NCT02849548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suvorexant
Description: First in class orexin antagonist approved by the FDA for the treatment of insomnia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pill with inactive ingredients
Study: NCT01785979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone induction - chloroquine
Description: At study entry, the patients will undergo physical examination and laboratory tests, including blood cell count, malaria microscopy, immune-chromatographic test for malaria antigen, malaria serology titers, and serum protein studies with immunoglobulin M quantification, immune-fixation and immunoglobulin free light chains measurement. We will assess all participants at 1, 3, 6 and 12 months after enrollment. Clinical examination and routine laboratory tests are done every 3 months during the follow-up period. Immunoglobulin M quantification and malaria serology are done at baseline, and at month 12 visit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: At study entry, the patients will undergo physical examination and laboratory tests, including blood cell count, malaria microscopy, immune-chromatographic test for malaria antigen, malaria serology titers, and serum protein studies with immunoglobulin M quantification, immune-fixation and immunoglobulin free light chains measurement. We will assess all participants at 1, 3, 6 and 12 months after enrollment. Clinical examination and routine laboratory tests are done every 3 months during the follow-up period. Immunoglobulin M quantification and malaria serology are done at baseline, and at month 12 visit.
Study: NCT00665600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol HCl
Description: Levalbuterol 0.63 TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol HCl
Description: Levabuterol 1.25 mg TID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol Sulfate
Description: Racemic albuterol 2.5 mg TID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo TID
Study: NCT03118128

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 850 mg PO three times a day plus prednisone in one 7-days cycle as pre-treatment and during the 28 days induction remission treatment, consolidation therapy and maintenance
Study: NCT00880347

Intervention type: DEVICE
Group type: OTHER
Intervention: Blood sampling
Description: Venous blood sampling in PaxGene tubes intended to collect blood RNA that will be then analyzed using SpliceArray (tm) technology for transcriptomic profile. sAPPalpha levels will be also dosed. Clinical data to be collected in parallel (medical history, concomitant treatment, MMSE,clinical examination,...)

Intervention type: DEVICE
Group type: OTHER
Intervention: Blood sampling
Description: Venous blood sampling in PaxGene tubes intended to collect blood RNA that will be then analyzed using SpliceArray (tm) technology for transcriptomic profile. sAPPalpha levels will be also dosed. Clinical data to be collected in parallel (medical history, concomitant treatment, MMSE,clinical examination,...)

Intervention type: DEVICE
Group type: OTHER
Intervention: Blood sampling
Description: Venous blood sampling in PaxGene tubes intended to collect blood RNA that will be then analyzed using SpliceArray (tm) technology for transcriptomic profile. sAPPalpha levels will be also dosed. Clinical data to be collected in parallel (medical history, concomitant treatment, MMSE,clinical examination,...)
Study: NCT04006665

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Ultrasonography (Baseline)
Description: Lung Ultrasonography will be performed prior to docking Robotic arms in basal three lung zones on both sides.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Ultrasonography ( At the end of surgery)
Description: Lung Ultrasonography will be performed after removal of Robotic arms and before extubation in basal three lung zones on both sides to assess degree of atelectasis.
Study: NCT01113593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol Fumarate
Description: Inhalation solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol Fumarate
Description: Inhalation solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foradil Aerolizer
Description: Dry powder inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foradil Aerolizer
Description: Dry powder inhaler
Study: NCT03031353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Misoprostol is given before elective cesarean section as prophylaxis against post partum hemorrhage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: placebos tablet will be given before elective Cesarean sections
Study: NCT01428622

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Respimat
Description: aqueous and ethanolic solution

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: aqueous and ethanolic solution

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respimat
Description: aqueous and ethanolic solution

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: aqueous and ethanolic solution

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: aqueous and ethanolic solution

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: aqueous and ethanolic solution

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: aqueous and ethanolic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olodaterol
Description: aqueous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol
Description: aqueous solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olodaterol
Description: aqueous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol
Description: aqueous solution
Study: NCT03633461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OC-02 (simpinicline) nasal spray
Description: OC-02 (simpinicline) nasal spray, 11.1 mg/ml
Study: NCT01428622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol
Description: aqueous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol
Description: aqueous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol
Description: aqueous solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olodaterol & BI54903
Description: ethanolic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol & BI54903
Description: ethanolic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olodaterol & BI54903
Description: ethanolic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol & BI54903
Description: ethanolic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol & BI54903
Description: ethanolic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol & BI54903
Description: ethanolic solution
Study: NCT03633461

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle) nasal spray
Description: Placebo (vehicle) nasal spray
Study: NCT01081002

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 10%
Description: 3 min before the endoscopy under propofol sedation 4 puffs of lidocaine 10% will be sprayed on the pharynx as a pharyngeal anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diluted gentian root solution
Description: As a basis, an infusion of water (45%), ethanol (35%) and gentian root cut will be used. The gentian root infusion is approved as a natural flavor in the food industry.3 min before the endoscopy under propofol sedation 4 puffs of this gentian root infusion will be sprayed on the pharynx as a pharyngeal anesthesia
Study: NCT00896974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retinoid 9cUAB30
Description: Given orally
Study: NCT02020278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tolvaptan 3.75-, 7.5-, 15-, and 30-mg spray-dried tablets. Dosage: Depending on age and weight, Tablet (3.75 mg - 60 mg daily). Frequency: Once daily.~Duration: Participants may be eligible to receive short-term or long-term optional tolvaptan treatment at any time during their participation in the trial, with one or more treatment cycles over a 6-month period.
Study: NCT04970303

Intervention type: DRUG
Intervention: Methylphenidate
Description: Retina or Concerta
Study: NCT01491451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS/INTERFIX™
Description: INTERFIX™ device containing recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the absorbable collagen sponge (ACS) carrier.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous bone/INTERFIX™
Description: INTERFIX™ device containing autogenous bone taken from the patient's iliac crest.
Study: NCT04685512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir disoproxil and emtricitabine
Description: Experimental drugs administration of 7-day short course TDF/FTC
Study: NCT01793493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation
Description: Participants are pooled in small groups (6-8 individuals). Each group participates to ten twice weekly meetings. Each CS session is run by one trained operator. One observer participates to the sessions to guarantee homogeneity between different operators. Exercises are structured with an increasing cognitive complexity and are tailored to the characteristics of the group.~Meetings (each lasting about 2 hours) have a common structure:~* body awakening (10 minutes)~* cognitive stimulation (1 hour and a half) scheduled as follow:~  * temporospatial orientation~ * attentional abilities~ * one of the following cognitive areas: language, executive functions, verbal and visual memory (encoding, consolidation, retrieval)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sanitary education
Description: Participants attend two weekly meetings (for a total of 3 hours) focused on lifestyle education and brain functioning.
Study: NCT00981487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 24 mg one time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 24 mg, on time in the am
Study: NCT03730207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xpede™ Bone Cement
Description: Xpede™ Bone Cement will be injected into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body by filling the bony trabeculae.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mendec Spine Bone Cement
Description: Mendec Spine Bone Cement will be injected into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body by filling the bony trabeculae.
Study: NCT02951754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate-release Methylphenidate
Description: Standard initial dose of 10 mg, twice or three times daily with doses increasing weekly until symptom control or occurrence of limiting adverse effects
Study: NCT03624192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RECELL® Autologous Cell Harvesting Device
Description: Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telfa™ Clear and Xeroform™ dressings
Description: Telfa™ Clear and Xeroform™ dressings
Study: NCT00725257

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: The recommended composition of the dietary regimen was as follows: Carbohydrate 40 to 50%, protein 15 to 20%; fat 30 to 40%; saturated fat less than 10%.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-fat diet
Description: The recommended composition of the dietary regimen was as follows: Fat less than 30%; carbohydrate 50 to 60%, protein 15 to 20%; saturated fat less than 10%.
Study: NCT02078700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The early palliative care programme
Description: The intervention consists of an early integration of a palliative care programme with the standard care performed by the oncologists-pneumologists that are following the cancer patients. The intervention will be delivered by the specialised Palliative Care Unit (PCU) of the hospital. Each patient meets the professionals of the PCU by 30 days by cancer diagnosis and at least monthly thereafter in the outpatint settings.
Study: NCT01358461

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: Blood sampling

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: Blood sampling
Study: NCT01428622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol & BI54903
Description: ethanolic solution
Study: NCT01358461

Intervention type: OTHER
Intervention: ECG-Holter 24 h tape and sino-carotid stimulation test
Description: ECG-Holter 24 h tape and sino-carotid stimulation test

Intervention type: OTHER
Intervention: ECG-Holter 24 h tape and sino-carotid stimulation test
Description: ECG-Holter 24 h tape and sino-carotid stimulation test
Study: NCT03135015

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo capsules
Description: 250ml water with 16 x 250mg placebo capsules

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo capsules
Description: 250ml water with 16 x 250mg placebo capsules

Intervention type: OTHER
Group type: OTHER
Intervention: 2g capsules
Description: 250ml water with 8 x 250mg capsules containing Axulin powder plus 8 x 250mg placebo capsules

Intervention type: OTHER
Group type: OTHER
Intervention: 2g capsules
Description: 250ml water with 8 x 250mg capsules containing Axulin powder plus 8 x 250mg placebo capsules

Intervention type: OTHER
Group type: OTHER
Intervention: 4g capsules
Description: 250ml water with 16 x 250mg capsules containing Axulin powder

Intervention type: OTHER
Group type: OTHER
Intervention: 4g capsules
Description: 250ml water with 16 x 250mg capsules containing Axulin powder

Intervention type: OTHER
Group type: OTHER
Intervention: Water Control
Description: 250ml water

Intervention type: OTHER
Group type: OTHER
Intervention: Water Control
Description: 250ml water
Study: NCT01428622

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BI54903
Description: ethanolic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI54903
Description: ethanolic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI54903
Description: ethanolic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI54903
Description: ethanolic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI54903
Description: ethanolic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI54903
Description: ethanolic solution
Study: NCT03135015

Intervention type: OTHER
Group type: OTHER
Intervention: 2g tablets
Description: 250ml water with 2 x 1g tablets containing Axulin powder

Intervention type: OTHER
Group type: OTHER
Intervention: 2g tablets
Description: 250ml water with 2 x 1g tablets containing Axulin powder

Intervention type: OTHER
Group type: OTHER
Intervention: 4g tablets
Description: 250ml water with 4 x 1g tablets containing Axulin powder
Study: NCT03117192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate
Description: Zinc supplementation in syrup form

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sucrose Syrup
Description: Sucrose as placebo, with same taste and consistency as zinc
Study: NCT03858621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl NOL guided
Description: Intervention is NOL monitoring in this group that will help to guide intravenous administration of fentanyl during surgery.
Study: NCT00555711

Intervention type: DEVICE
Intervention: Modulated Imaging
Description: Modulated Imaging
Study: NCT03135015

Intervention type: OTHER
Group type: OTHER
Intervention: 4g tablets
Description: 250ml water with 4 x 1g tablets containing Axulin powder
Study: NCT03481582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Description: (nitrodermal®) 5 mg (patch)as a source of Nitric oxide from 2nd day of cycle till maturation of the follicles ≥ 18 mm just for one cycle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Three dimensional power doppler
Description: Once the follicle reached ≥18 mm 3D power Doppler will be used to assess the uterine and subendometrial blood flow

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Three dimensional power doppler
Description: Once the follicle reached ≥18 mm 3D power Doppler will be used to assess the uterine and subendometrial blood flow
Study: NCT00560820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: 30 mg/kg/day
Study: NCT03788343

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phenylalanine
Description: The study product Phenylalanine, a dietary supplement, is authorized in Switzerland, but not designated for this patient group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules are indistinguishable in their appearance from Phe capsules
Study: NCT02548169

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC Vaccine + Standard of Care Chemotherapy
Description: 4 doses of DC vaccine at 2 weeks interval, combined with either:~* Standard of care neoadjuvant folinic acid, oxaliplatin, irinotecan and 5- Fluorouracil (5FU) (FOLFIRINOX) regimen alone (6 cycles)~* FOLRIRINOX regimen followed by 5-FU chemoradiation or Gemcitabine Chemoradiation~* Gemcitabine + nab-paclitaxel~The first vaccination will include one intradermal injection of 100 μL at 15 x106 cells/mL in the upper thigh and one subcutaneous injection of 1 mL (15 x 106 cells/mL) .~The participants will receive 3 additional subcutaneous vaccinations, each injection of 1 mL at 15 x 106 cells/mL, at 2 weeks interval, on Day 2 of study weeks 3, 5 and 7.~Participants will receive 2 booster DC vaccinations subcutaneously of 1 mL at 15x106 cells/mL.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC Vaccine + Standard of Care Chemotherapy
Description: 4 doses of DC vaccine at 2 weeks interval, combined with either:~* Standard of care neoadjuvant folinic acid, oxaliplatin, irinotecan and 5- Fluorouracil (5FU) (FOLFIRINOX) regimen alone (6 cycles)~* FOLRIRINOX regimen followed by 5-FU chemoradiation or Gemcitabine Chemoradiation~* Gemcitabine + nab-paclitaxel~The first vaccination will include one intradermal injection of 100 μL at 15 x106 cells/mL in the upper thigh and one subcutaneous injection of 1 mL (15 x 106 cells/mL) .~The participants will receive 3 additional subcutaneous vaccinations, each injection of 1 mL at 15 x 106 cells/mL, at 2 weeks interval, on Day 2 of study weeks 3, 5 and 7.~Participants will receive 2 booster DC vaccinations subcutaneously of 1 mL at 15x106 cells/mL.